BUZZ-BioRestorative rises on preliminary data for bone disease cell therapy

Reuters
2024-11-13

** Shares of drug developer BioRestorative Therapies

rise ~7% to $1.75 premarket

** Co reports preliminary data from ongoing mid-stage study testing BRTX-100, its lead cell therapy candidate to treat chronic lumbar disc disease

** Lumbar disc disease, also known as degenerative disc disease, occurs when spinal discs in lower back area begins to wear away

** No serious side-effects were reported in 10 safety run-in subjects, BRTX says

** Co says blinded data from 10 trial participants showed BRTX-100 helped improve pain and function

** Up to last close, stock down ~6% YTD

(Reporting by Mariam Sunny in Bengaluru)

((Mariam.ESunny@thomsonreuters.com;))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10